Results 61 to 70 of about 5,998 (173)

Real‐World Effectiveness of Tolvaptan for Hyponatremia in Cirrhosis Across Global Regions: A Target Trial Emulation

JGH Open, Volume 10, Issue 4, April 2026.
ABSTRACT Background Tolvaptan promotes electrolyte‐free water excretion and is widely used in Asia for ascites, but in Western countries its use is limited to hyponatremia because of hepatotoxicity concerns. Methods We performed a retrospective cohort study using the TriNetX Research Network, emulating a target trial of cirrhotic patients with ...
Kazuya Okushin, Ryosuke Tateishi, Mitsuhiro Fujishiro, Takeya Tsutsumi, Kazuhiko Koike, Tomohiro Tanaka   +5 more
wiley   +1 more source

INTERACTION OF BUMETANIDE AND KANAMYCIN

Nippon Jibiinkoka Gakkai Kaiho, 1978
In the present study, rabbits were treated with kanamycin in combination with a new loop diuretic bumetanide at a dosage level equipotent to the diuretic action of furosemide. Severe outer hair cell damage occurred in animals following the combined administration of bumetanide and kanamycin, and the damage was approximately equal to that of animals ...
OHTANI, IWAO, OHTSUKI, KOHSEI, OMATA, TAKEO, OUCHI, JIN, SAITO, TAKEO   +4 more
openaire   +2 more sources

Bumetanide [PDF]

Reactions Weekly, 2021
  +4 more sources

Bumetanide-Enhanced Phenobarbetal in Neonatal Seizure Model

Pediatric Neurology Briefs, 2008
Anticonvulsant efficacy of phenobarbital, bumetanide, and a combination of these drugs was studied in an in vitro hippocampal rat pup (4-7 days) preparation, with recurrent seizures induced by exposure to low-Mg solution, at the Department of Neurology ...
J Gordon Millichap
doaj   +1 more source

Neonatal Seizure Models to Study Epileptogenesis

Frontiers in Pharmacology, 2018
Current therapeutic strategies for epilepsy include anti-epileptic drugs and surgical treatments that are mainly focused on the suppression of existing seizures rather than the occurrence of the first spontaneous seizure.
Yuka Kasahara, Yuji Ikegaya, Ryuta Koyama   +2 more
doaj   +1 more source

Bumetanide increases Cl--dependent short-circuit current in late distal colon: Evidence for the presence of active electrogenic Cl- absorption.

PLoS ONE, 2017
Mammalian colonic epithelia consist of cells that are capable of both absorbing and secreting Cl-. The present studies employing Ussing chamber technique identified two opposing short-circuit current (Isc) responses to basolateral bumetanide in rat ...
Lieqi Tang, Xiefan Fang, Steven P Winesett, Catherine Y Cheng, Henry J Binder, Scott A Rivkees, Sam X Cheng   +6 more
doaj   +1 more source

Hydroxyapatite Nanorods Based Drug Delivery Systems for Bumetanide and Meloxicam, Poorly Water Soluble Active Principles

Nanomaterials
Poorly water-soluble drugs represent a challenge for the pharmaceutical industry because it is necessary to find properly tuned and efficient systems for their release.
Valeria Friuli, Lauretta Maggi, Giovanna Bruni, Francesca Caso, Marcella Bini   +4 more
doaj   +1 more source

Exit interviews from two randomised placebo-controlled phase 3 studies with caregivers of young children with autism spectrum disorder

Frontiers in Child and Adolescent Psychiatry
IntroductionAutism spectrum disorder (ASD) is characterised by difficulty with social communication and restricted, repetitive patterns of behaviour. This study aimed to improve understanding of the ASD patient experience with the treatment (bumetanide ...
Natalia Hawken, Bruno Falissard, Carl Choquet, Clement Francois, Jean Tardu, Ramona Schmid   +5 more
doaj   +1 more source

Synthesis of new sulfoximines and sulfonimidamides derivatives as NKCC1 inhibitors

Frontiers in Chemistry
IntroductionThe Na–K–2Cl cotransporter isoform 1 (NKCC1) regulates cell volume and ionic distribution, thereby also controlling the efficacy of neuronal GABAergic inhibition. enhanced activity of the NKCC1 chloride importer and high Cl.
Gerald Coste, Vincent Rodeschini, Pascal George, Eric Delpire, Yehezkel Ben-Ari, Yehezkel Ben-Ari   +5 more
doaj   +1 more source

Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD

Biomedicines
This study aimed to evaluate the safety and tolerability of STP1, a combination of ibudilast and bumetanide, tailored for the treatment of a clinically and biologically defined subgroup of patients with Autism Spectrum Disorder (ASD), namely ASD ...
Craig A. Erickson, Laura Perez-Cano, Ernest V. Pedapati, Eric Painbeni, Gregory Bonfils, Lauren M. Schmitt, Hannah Sachs, Meredith Nelson, Lisa De Stefano, Grace Westerkamp, Adriano L. S. de Souza, Oliver Pohl, Offir Laufer, Gil Issachar, Thomas Blaettler, Jean-Marc Hyvelin, Lynn A. Durham   +16 more
doaj   +1 more source